A third of her crop is gone —
to a disease she never saw.
Everyone guesses. Everyone loses.
Linda's loss is everyone's loss, repeated millions of times a year.
lost every year to cassava disease in East & Central Africa alone.
of global crop yield destroyed by pests & plant disease, every year.
annual cost to the global economy (FAO estimate).
This isn't an edge case. It's a structural, recurring tax — paid in food and livelihoods by the people who can least afford it.
Like crops, biological threats hamper livelihoods and the economy across every domain.
Every one shares the same root cause: a decision needed in situ — but data only available from a distant lab, days later.
What if the blind spot closed — one domain at a time?
Same four domains as the problem — now with the risk turned down, in situ, in minutes.
What if we could detect the biomarkers of disease accurately, in situ, with no lab — and turn every reading into the intelligence that drives biological risk toward zero?
Not one disease. Any biomarker. That's the company we're building — cassava is simply where we prove it.
We're co-founders and bioengineers out of Imperial — a CTO who invented the science, a CEO who shipped the product.
Imperial PhD (Güder Lab). ELLA co-inventor; owns the science, v1 product & manufacturing, next-gen impedance platform (patent pending).
Biomedical engineer bridging Imperial deep-tech to market. Owns BD, fundraising, IP/data governance, and the entire live software stack.
Leads the Güder Lab, a world-class paper-diagnostics group. Holds the Gates relationship, grant base and lab resourcing.
Behind us: José Flauzino & Laura Gonzalez Macias (lead inventors), an Imperial wet-lab bench, partners IITA · IFAD · GAIN.
Lab-grade detection,
in the field.
ELLA turns any lateral-flow test — the most universal diagnostic format on earth — into a quantitative, GPS-tagged digital read. Battery-free, NFC tap from any phone, sub-$1 per test. Biomarker-agnostic by design.
- First proof — CBSD, field-validated in East Africa with IITA: 89% agreement with RT-qPCR · ~95–97% with ELISA — the two gold standards, in real field samples.
- It generalises: procalcitonin, folate, respiratory viruses, ferritin/Vit D — 7+ validated, thousands adaptable.
2 granted Imperial patents · Biosensors & Bioelectronics (2024) · Flauzino et al. 2025 preprint.
Every tap becomes a point on the map.
The ELLA app captures each read — result in under a minute, geotagged, timestamped — and syncs to the cloud. The dashboard aggregates thousands into a live surveillance picture a programme can act on.
Live today at dashboard.superposition.bio — multi-tenant, the centrepiece of our Gates demo. This stack is built, not promised.
The dataset becomes the moat.
The AI turns it into decisions.
Cheap quantitative reads at scale → chemical datasets no one else can assemble. Every biomarker a new dataset; every tap a new row.
ML fusing diagnostics with weather, soil & agronomy to predict risk and recommend the action — spray, accept/reject, treat/don't.
Replication cost ≈ zero → scales at AI/data multiples (6–10×+). We sell certainty, not cassettes.
The device is the on-ramp; the data layer is the defensible asset — and it compounds with every deployment.
We start with cassava — then the platform expands in three directions.
More volume of the same use case — every new cassava site, buyer and region. Same product, more reads.
More use cases. The read is already proven across 7+ biomarkers — banana, sepsis/AMR, folate, respiratory, ferritin/Vit D. One method, four domains.
The data layer compounds — more reads → sharper predictions → new markets for intelligence and a self-improving reduction of biological risk.
The only platform at the convergence of four large, fragmented domains plus a compounding data layer. Headline TAM ~$60B today → ~$95B by 2030. The opportunity is huge.
We're raising an
$8M seed.
To commercialise CBSD detection and fund the first high-value expansions.
$8M so farmers like Linda don't lose a crop to a disease they couldn't see. One platform. Countless biomarkers.
We're also opening a handful of pilot partnerships — warm intros to anyone wanting to turn a biological blind spot into a measured, managed risk are welcome.
Thank you. · Thank you.